Skip to content

Climb Bio, Inc. CLYM Prepaid & Other Current

Prepaid & Other Current at other companies

Artesian Resources logo
Artesian ResourcesARTNA
-$670K-80.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$9M-47.1%
AAR Corp logo
AAR CorpAIR
$1M-84.1%
BDC
BTC Development Corp. BDCI
$46.73K+40.6%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$2.49M+378%
SAC
Safeguard Acquisition SAC
-$7.24K

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpensesOther.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s prepaid & other current?
Climb Bio, Inc. (CLYM) reported prepaid & other current of -$929K in Q1 2026.
How has Climb Bio, Inc.'s prepaid & other current changed year-over-year?
Climb Bio, Inc.'s prepaid & other current increased by 50.9% year-over-year, from -$1.89M to -$929K.
What is the long-term trend for Climb Bio, Inc.'s prepaid & other current?
Over 2 years (2021 to 2025), Climb Bio, Inc.'s prepaid & other current has grown at a -72.9% compound annual growth rate (CAGR), from $11.1M to $816K.
What does prepaid & other current mean?
Tracks changes in payments made in advance for goods or services to be received in future periods, such as insurance or research contracts. A significant change in this balance can indicate shifts in the company's near-term operational commitments or procurement strategy.